mRNA Manufacturing Patents: Who Leads, Where the Gaps Are 2026
mRNA manufacturing and capping patents: mapping who controls in vitro transcription and purification
22.2% concentration at the top. The five leading assignees account for 12,703 of 57,322 records in scope — dense but not a monopoly. Annual filings rose from 1,047 in 2017 to a peak of 1,754 in 2022, then eased to 1,363 by 2024 (the last complete year) — a -6% move over 2021-2024. 2025 and 2026 figures are still filling in under the publication lag and should not be read as a decline in current activity.
- 1IMMATICS BIOTECHNOLOGIES GMBH6.9%
- 2THE TRUSTEES OF THE UNIV OF PENNSYLVANIA4.2%
- 3BIONTECH SE4.1%
- 4MODERNATX INC3.9%
- 5MASSACHUSETTS INST OF TECH3.0%
See the full mrna manufacturing and capping analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about mRNA manufacturing patents
Who holds the most patents in mRNA manufacturing and capping?
The ranked leader in this dataset holds 3,939 records, notably ahead of fifth place at 1,739 and tenth place at 1,310. The top five assignees combined account for 22.2% of all 57,322 records in scope, and the top ten reach 34.6%. That leaves roughly two-thirds of the field held by a long tail of smaller filers, so a single company’s lead does not translate into control of the whole manufacturing process space.
Is mRNA manufacturing patent filing still growing?
Filings rose steadily to a peak of 1,754 in 2022, then eased to 1,363 by 2024 — a -6% move over the 2021-2024 span, using the last year that can be treated as complete. Numbers for 2025 and 2026 look much lower, but that reflects the roughly 18-month lag between filing and publication rather than an actual drop in R&D activity. Any claim that the field is shrinking should be checked against complete-year data only.
What technical areas are most crowded in mRNA manufacturing patents?
C12N (microorganisms and genetic engineering) and A61K (medicinal preparations) are the densest classes, touching 23.1% and 20.6% of the 57,322 records respectively. C07K (peptides and proteins) and A61P (therapeutic activity) follow at 10.4% and 8.2%. These classes cover the core transcription chemistry and formulation claims, which is where new filings face the heaviest prior art.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on mRNA Manufacturing and Capping covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.